Special Offers
100% Performance Guaranteed
Key Specifications Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H, Ht, Mk, R, Fe | ELISA, IP, WB, ICC, IHC | M | Purified | Monoclonal Antibody |
| Description | |
|---|---|
| Catalogue Number | MAB4051 |
| Brand Family | Chemicon® |
| Trade Name |
|
| Description | Anti-Angiotensin Converting Enzyme Antibody, clone 9B9 |
| Alternate Names |
|
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Purified immunoglobulin. Liquid in PBS, pH 7.4, 150 mM NaCl containing 0.05% sodium azide. |
| Quality Level | MQ100 |
| Applications | |
|---|---|
| Application | Anti-Angiotensin Converting Enzyme Antibody, clone 9B9 detects level of Angiotensin Converting Enzyme & has been published & validated for use in ELISA, IP, WB, IC, IH. |
| Key Applications |
|
| Applications Not Recommended |
|
| Application Notes | Immunohistochemistry (Danilov et al., 1987; Falkenhahn et al., 1995; Morrell et al., 1995) : 1:1,000 on fresh frozen or 4% paraformaldehyde fixed tissues. Does not work on paraffin embedded tissue. Immunocytochemistry: 1:100. Reacts with endothelial cell, macrophages (activated) and THP1 cells (monocyte line). Immunoblotting: 1:100: ~170-180kDa isoform, reducing conditions. Immunoprecipitation: 1:1,000-1:10,000 ELISA : 1:1,000 Visualization of lung vessels (Danilov et al., 1989; Klibanov et al., 1988; Hiemisch et al., 1993) Antibody mediated drug delivery into the lung (Danilov et al., 1991, 1994; Muzykantov et al., 1994, 1996) Estimation of lung vessel injury (Muzykantov et al., 1991; Atochina et al., 1992) Structure-function of ACE (Danilov et al., 1994) Optimal working dilutions must be determined by the end user. |
| Biological Information | |
|---|---|
| Immunogen | Angiotensin-converting enzyme from human lung |
| Clone | 9B9 |
| Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. |
| Host | Mouse |
| Specificity | Angiotensin-converting enzyme [ACE] (N-terminal), no reactivity to testicular/germinal form of human ACE (90kDa isoform) |
| Isotype | IgG1 |
| Species Reactivity |
|
| Antibody Type | Monoclonal Antibody |
| Entrez Gene Number |
|
| Entrez Gene Summary | This gene encodes an enzyme involved in catalyzing the conversion of angiotensin I into a physiologically active peptide angiotensin II. Angiotensin II is a potent vasopressor and aldosterone-stimulating peptide that controls blood pressure and fluid-electrolyte balance. This enzyme plays a key role in the renin-angiotensin system. Many studies have associated the presence or absence of a 287 bp Alu repeat element in this gene with the levels of circulating enzyme or cardiovascular pathophysiologies. Two most abundant alternatively spliced variants of this gene encode two isozymes - the somatic form and the testicular form that are equally active. Multiple additional alternatively spliced variants have been identified but their full length nature has not been determined. |
| Gene Symbol |
|
| UniProt Number |
|
| UniProt Summary | FUNCTION: SwissProt: P22966 # Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.| P12821 # Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. COFACTOR: Binds 1 zinc ion per subunit. & Binds 2 chloride ions per subunit. SIZE: 732 amino acids; 83330 Da SUBCELLULAR LOCATION: Angiotensin-converting enzyme, testis- specific isoform, soluble form: Secreted. & Cell membrane; Single-pass type I membrane protein. TISSUE SPECIFICITY: Spermatocytes, adult testis. DOMAIN: SwissProt: P22966 PTM: Phosphorylated by CK2 on Ser-725; which allows membrane retention (By similarity). DISEASE: SwissProt: P12821 # Genetic variations in ACE may be a cause of susceptibility to ischemic stroke [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors. & Defects in ACE are a cause of renal tubular dysgenesis (RTD) [MIM:267430]. RTD is an autosomal recessive severe disorder of renal tubular development characterized by persistent fetal anuria and perinatal death, probably due to pulmonary hypoplasia from early-onset oligohydramnios (the Potter phenotype). & Genetic variations in ACE can influence susceptibility to diabetic nephropathy [MIM:603933]. Diabetic nephropathy is a kidney disease and resultant kidney function impairment due to the long standing effects of diabetes on the microvasculature (glomerulus) of the kidney. Features include increased urine protein and declining kidney function. SIMILARITY: SwissProt: P22966 ## Belongs to the peptidase M2 family.| P12821 ## Belongs to the peptidase M2 family. MISCELLANEOUS: The glycosidase activity probably uses different active site residues than the metalloprotease activity. & Inhibitors of ACE are commonly used to treat hypertension and cardiac dysfunction. |
| Product Usage Statements | |
|---|---|
| Usage Statement |
|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles. |
| Packaging Information | |
|---|---|
| Material Size | 100 µg |